211 related articles for article (PubMed ID: 36160103)
1. Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma.
Sa HS; Daniel C; Esmaeli B
J Ophthalmic Vis Res; 2022; 17(3):405-412. PubMed ID: 36160103
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
Finger PT; Pavlick AC
J Immunother Cancer; 2019 Mar; 7(1):83. PubMed ID: 30909967
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma.
Hong BY; Ford JR; Glitza IC; Torres Cabala CA; Tetzlaff M; Prieto VG; Parker R; Daniel C; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2021 Jan-Feb 01; 37(1):e9-e13. PubMed ID: 32618825
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitors in Cancer Therapy.
Shiravand Y; Khodadadi F; Kashani SMA; Hosseini-Fard SR; Hosseini S; Sadeghirad H; Ladwa R; O'Byrne K; Kulasinghe A
Curr Oncol; 2022 Apr; 29(5):3044-3060. PubMed ID: 35621637
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
8. Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies.
Gkiala A; Palioura S
Clin Ophthalmol; 2020; 14():3137-3152. PubMed ID: 33116365
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
Ottaviano M; De Placido S; Ascierto PA
Virchows Arch; 2019 Apr; 474(4):421-432. PubMed ID: 30747264
[TBL] [Abstract][Full Text] [Related]
11. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
[TBL] [Abstract][Full Text] [Related]
12. Treatment response and recurrence of conjunctival melanoma with orbital invasion treated with immune checkpoint inhibitors: case report and literature review.
Alhammad FA; Alburayk KB; Albadri KS; Butt SA; Azam F
Orbit; 2024 Feb; 43(1):49-57. PubMed ID: 37052129
[TBL] [Abstract][Full Text] [Related]
13. [Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors].
Rokohl AC; Koch KR; Mor JM; Loreck N; Schlaak M; Mauch C; Bechrakis NE; Mohi A; Kakkassery V; Heindl LM
Ophthalmologe; 2020 Jun; 117(6):521-527. PubMed ID: 31938823
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
15. Conjunctival Melanoma: Current Treatments and Future Options.
Grimes JM; Shah NV; Samie FH; Carvajal RD; Marr BP
Am J Clin Dermatol; 2020 Jun; 21(3):371-381. PubMed ID: 31965542
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor-associated Uveitis: Review of Treatments and Outcomes.
Dow ER; Yung M; Tsui E
Ocul Immunol Inflamm; 2021 Jan; 29(1):203-211. PubMed ID: 32815757
[No Abstract] [Full Text] [Related]
17. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
18. Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma.
Dimitriou F; Hauschild A; Mehnert JM; Long GV
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-22. PubMed ID: 35658500
[TBL] [Abstract][Full Text] [Related]
19. Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience.
Indini A; Di Guardo L; Cimminiello C; Lorusso D; Raspagliesi F; Del Vecchio M
J Gynecol Oncol; 2019 Nov; 30(6):e94. PubMed ID: 31576688
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa.
Ford J; Thuro BA; Thakar S; Hwu WJ; Richani K; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2017; 33(4):e82-e85. PubMed ID: 27662198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
